654 Results

People

  1. Motzer
    Motzer
  2. Mulhall
    Mulhall
  3. Saltz
    Saltz
  4. Hudis
    Hudis
  5. Abou-Alfa
    Abou-Alfa
  6. Lichtman
    Lichtman
  7. De Angelis
    De Angelis
  8. Ginsberg
    Ginsberg
  9. Russo
    Russo
  10. Feldman
    Feldman

Groups

  1. Department of Medicine (397)
  2. Solid Tumor Oncology Division (270)
  3. Hematologic Malignancies, Division of (99)
  4. Genitourinary Oncology Service (98)
  5. Survivorship Research (97)
  6. Surgery (84)
  7. Division of Subspecialty Medicine (78)
  8. Center for Hematologic Malignancies (77)
  9. Epidemiology and Biostatistics (69)
  10. Radiology, Department of (61)
  1. "hypertension"
Formats
  1. Journal Article (607)
  2. Review (31)
  3. Editorial (6)
  4. Guidelines (4)
  5. Research Letter (3)
  6. Book Section (1)
  7. Conference Paper (1)
  8. Correspondence (1)
Groups
  1. Department of Medicine (397)
  2. Solid Tumor Oncology Division (270)
  3. Hematologic Malignancies, Division of (99)
  4. Genitourinary Oncology Service (98)
  5. Survivorship Research (97)
  6. Surgery (84)

More Groups

People
  1. Robert Motzer (59)
  2. John Mulhall (21)
  3. Leonard Saltz (18)
  4. Clifford Hudis (16)
  5. Richard Steingart (14)
  6. Ghassan Abou-Alfa (13)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (31)
  4. 2022 (29)
  5. 2021 (23)
  6. 2020 (38)

More Years

Publications
  1. Journal of Clinical Oncology (41)
  2. Clinical Cancer Research (20)
  3. Lancet Oncology (20)
  4. Cancer (15)
  5. Journal of the National Comprehensive Cancer Network (15)
  6. Journal of Sexual Medicine (14)

More Publications

Publishers
  1. Elsevier Inc. (124)
  2. Elsevier Science, Inc. (58)
  3. Springer (47)
  4. American Society of Clinical Oncology (42)
  5. Oxford University Press (39)
  6. Wiley Blackwell (35)

More Publishers

Results (654)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial
    Journal Article

    Blay, J. Y.; Serrano, C.; Heinrich, M. C.; Zalcberg, J.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Intraductal papillary squamous neoplasm of the pancreas: Cyto-histologic correlation of a novel entity
    Journal Article

    Hagen, C. E.; Christians, K.; Hopp, A.; Giorgadze, T.; Hartley, C. P.; Hunt, B.; Basturk, O.; Klimstra, D.
    Annals of Diagnostic Pathology (2020)

    Fulltext@MSK | Save
  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: A randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Journal Article

    Landgren, C. O.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P.; Estell, J. A.; Sandhu, I.; Jenner, M. W.; Williams, C.; Cavo, M.; more...
    Leukemia (2020)

    Fulltext@MSK | Save
  • BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
    Journal Article

    Stanchina, M.; McKinnell, Z.; Park, J. H.; Stein, E. M.; Cai, S. F.; Taylor, J.
    Leukemia Research Reports (2020)

    Fulltext@MSK | Save
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study
    Journal Article

    Dimopoulos, M.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D.; Weisel, K.; Yang, H.; Klippel, Z.; Zahlten-Kumeli, A.; more...
    Lancet (2020)

    Fulltext@MSK | Save
  • DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
    Journal Article

    Wudhikarn, K.; Pennisi, M.; Garcia-Recio, M.; Flynn, J. R.; Afuye, A.; Silverberg, M. L.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; Shah, G. L.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save
  • Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage
    Review

    Choi, K. J.; Nam, J. K.; Kim, J. H.; Choi, S. H.; Lee, Y. J.
    Experimental and Molecular Medicine (2020)

    Fulltext@MSK | Save
  • Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma
    Journal Article

    Kelley, R. K.; Mollon, P.; Blanc, J. F.; Daniele, B.; Yau, T.; Cheng, A. L.; Valcheva, V.; Marteau, F.; Guerra, I.; Abou-Alfa, G. K.
    Advances in Therapy (2020)

    Fulltext@MSK | Save
  • Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology
    Review

    Arora, S. P.; Liposits, G.; Caird, S.; Dunne, R. F.; Moffat, G. T.; Okonji, D.; Rodriquenz, M. G.; Dua, D.; Dotan, E.
    Journal of Geriatric Oncology (2020)

    Fulltext@MSK | Save